Home/Pipeline/BoxX-NoAF Clinical Trial

BoxX-NoAF Clinical Trial

Prevention of new-onset post-operative atrial fibrillation

N/A (Pivotal Trial)Active

Key Facts

Indication
Prevention of new-onset post-operative atrial fibrillation
Phase
N/A (Pivotal Trial)
Status
Active
Company

About AtriCure

AtriCure is a commercial-stage medical device company specializing in cardiac surgical ablation and left atrial appendage exclusion for atrial fibrillation, alongside a growing cryoanalgesia platform for post-operative pain management. The company has established a significant commercial footprint with its AtriClip LAA management devices and Isolator ablation systems, supported by ongoing clinical trials like BoxX-NoAF to expand indications. Its strategic focus is on providing minimally invasive, often opioid-sparing, solutions for complex surgical needs in cardiothoracic and pain management settings.

View full company profile